13F Holdings
中文EN

OGI ORGANIGRAM GLOBAL INC. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1620737 · Reporting currency CAD · Fiscal year ends 09/30

Financial factors as of 2022-08-31 (FY2022), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY84.2%
TTM net income YoY89.1%
TTM EPS YoY63.9%
Revenue 3-yr CAGR21.9%
Net income 3-yr CAGR—

Margins

Gross margin21.7%
Operating margin-29.6%
Net margin-9.8%
FCF margin-58.3%
EBITDA margin-26.0%

Returns

ROE-2.9%
ROA-2.5%
ROIC (approx.)-7.9%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets12.0%
Debt / equity0.00x
Current ratio4.01x
Interest coverage-100.59x

Cash quality & payout

Operating cash flow / net income2.54x
Accruals ratio3.9%
Payout ratio—
Capex / revenue33.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: CAD FY2024*2024-09-30FY2022*2022-08-31FY2021*2021-08-31FY2020*2020-08-31FY2019*2019-08-31
Income statement
Revenue159.84M145.81M79.16M86.80M80.41M
Cost of revenue111.39M119.04M103.57M105.00M42.52M
Gross profit47.52M31.57M-28.40M-56.49M48.47M
R&D expense11.20M5.96M3.65M1.27M409,000
SG&A expense45.87M42.91M29.92M28.00M18.59M
Operating income-35.67M-43.15M-91.82M-145.51M5.49M
Interest expense—429,0002.96M6.01M9.67M
Pretax income-45.44M-14.37M-130.70M-146.63M-5.88M
Income tax0-88,0000-10.47M3.63M
Net income-45.44M-14.28M-130.70M-136.16M-9.54M
EBITDA-31.82M-37.85M-89.35M-144.00M6.15M
EPS (basic)-0.48-0.18-0.51-0.79-0.07
EPS (diluted)-0.48-0.18-0.51-0.79-0.07
Weighted avg. shares (diluted)95.29M77.23M256.12M178.06M151.54M
Balance sheet
Cash & equivalents106.75M68.52M55.37M24.60M47.55M
Receivables37.15M46.37M21.04M14.75M16.54M
Inventory67.35M50.31M36.70M66.36M93.14M
Current assets262.22M221.62M260.62M170.20M196.28M
PP&E, netmay include right-of-use assets (IFRS)96.23M259.82M235.94M247.42M218.47M
Intangibles—56.24M17.05M1.77M2.07M
Total assets407.86M577.11M554.02M435.13M428.52M
Current liabilities53.32M55.28M26.27M29.08M43.86M
Short-term debt60,00080,00080,00011.60M3.51M
Long-term debt25,000155,000230,000103.67M46.07M
Total debt85,000235,000310,000115.27M49.58M
Total liabilities101.87M69.05M74.21M135.60M101.52M
Shareholders' equity305.99M508.06M479.81M299.53M327.01M
Net debt-106.66M-68.28M-55.05M90.67M2.02M
Shares outstanding108.59M78.45M74.70M194.51M156.20M
Cash flow statement
Operating cash flow3.87M-36.21M-28.59M-45.12M-35.08M
Capital expenditure4.73M48.75M11.76M77.22M108.76M
Free cash flow-859,000-84.96M-40.35M-122.35M-143.84M
Investing cash flow-38.77M44.03M-115.11M-138.20M-46.78M
Financing cash flow107.78M5.33M174.46M160.37M74.33M
Depreciation & amortization3.85M5.30M2.47M1.51M664,000
Stock-based compensation7.18M5.13M3.90M7.80M14.89M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.